Recipharm and LobSor Pharmaceuticals Sign Manufacturing Agreement for Parkinson’s Treatment

September 8, 2015
Pharmaceutical Technology Editors

This agreement is a follow-on to an established collaboration between LobSor and Recipharm for the development and the manufacturing of Lecigon batches for the recently completed clinical trial.

Recipharm and privately owned Swedish pharmaceutical company LobSor Pharmaceuticals have entered into an agreement for the manufacturing of Lecigon, a proprietary treatment for advanced Parkinson’s disease. Lecigon is the first product developed by LobSor in close collaboration with Recipharm.

Under the terms of the agreement, Recipharm will have exclusive manufacturing rights for volumes representing first three years of commercial sales. Recipharm will also support development costs against a mark-up on manufacturing prices, up to a certain volume, when Lecigon is produced for commercial sales.  

This agreement is a follow-on to an established collaboration between LobSor and Recipharm for the development and the manufacturing of batches for the recently completed clinical trial.

Source: Recipharm